Dyck L E
Biochem Pharmacol. 1987 Apr 15;36(8):1373-6. doi: 10.1016/0006-2952(87)90097-9.
A number of inhibitors of L-aromatic amino acid decarboxylase (AAD) and monoamine oxidase (MAO) were tested to determine whether they also inhibited tyrosine aminotransferase (TAT). The AAD inhibitors carbidopa, NSD-1015, NSD-1034 and Ro4-5127 inhibited liver TAT. Carbidopa inhibited brain AAD and liver TAT equally well. In contrast, other AAD inhibitors (Ro4-4602 and alpha-monofluoromethyldopa) did not inhibit TAT. Phenelzine, an MAO inhibitor, inhibited liver TAT, but other MAO inhibitors (tranylcypromine and isocarboxazid) did not. Systemic administration of those drugs that were found to be inhibitors of TAT in vitro caused significant increases in rat brain p-tyrosine levels.
测试了多种L-芳香族氨基酸脱羧酶（AAD）和单胺氧化酶（MAO）抑制剂，以确定它们是否也抑制酪氨酸转氨酶（TAT）。AAD抑制剂卡比多巴、NSD-1015、NSD-1034和Ro4-5127抑制肝脏TAT。卡比多巴对脑AAD和肝脏TAT的抑制作用同样良好。相比之下，其他AAD抑制剂（Ro4-4602和α-单氟甲基多巴）不抑制TAT。单胺氧化酶抑制剂苯乙肼抑制肝脏TAT，但其他单胺氧化酶抑制剂（反苯环丙胺和异卡波肼）则不然。对那些在体外被发现是TAT抑制剂的药物进行全身给药，会使大鼠脑对酪氨酸水平显著升高。
